REVOLVE or PureGraft Technique in Processing Fat Grafts for Patients Undergoing Breast Reconstruction
NCT ID: NCT03502512
Last Updated: 2021-08-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
20 participants
INTERVENTIONAL
2018-02-13
2021-08-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Prospective Study of Autologous Fat Grafting for Breast Augmentation
NCT00663156
Study of Autologous Fat Enhanced w/ Regenerative Cells Transplanted to Reconstruct Breast Deformities After Lumpectomy
NCT00616135
Autologous Fat Grafting in Radiated Soft Tissue Reconstruction
NCT05890196
Delayed-Immediate Breast Reconstruction
NCT00473122
Immunophenotyping of Fresh Stromal Vascular Fraction From Adipose Derived Stem Cells (ADSC) Enriched Fat Grafts
NCT01771913
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. To measure and compare the rate of fat graft retention, defined as the rate between the volume of fat remaining in the surgical site at one year and the volume of fat at baseline, associated with the use of two aforementioned adipose tissue processing techniques.
SECONDARY OBJECTIVES:
I. To measure early post-operative complications including infection, hematoma, delayed wound healing or seroma.
II. To measure late complications associated with fat grafting including fat necrosis, cyst formation, palpable mass, or breast asymmetry.
III. To measure patient reported outcomes (PRO, BREAST-Questionnaire \[Q\], Body Image Survey).
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients undergo reconstructive surgery with REVOLVE technique.
ARM II: Patients undergo reconstructive surgery with PureGraft technique.
After completion of study, patients are followed up at 2-4 weeks and then once a year for up to 2 years.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm I (REVOLVE technique)
Patients undergo reconstructive surgery with REVOLVE technique.
Questionnaire Administration
Ancillary studies
Reconstructive Surgery
Undergo reconstructive surgery with REVOLVE technique
Arm II (PureGraft technique)
Patients undergo reconstructive surgery with PureGraft technique.
Questionnaire Administration
Ancillary studies
Reconstructive Surgery
Undergo reconstructive surgery with PureGraft technique
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Questionnaire Administration
Ancillary studies
Reconstructive Surgery
Undergo reconstructive surgery with REVOLVE technique
Reconstructive Surgery
Undergo reconstructive surgery with PureGraft technique
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with available harvest sites for fat grafting
* Patients with body mass index (BMI) \> 20
* Anticipated harvested fat volume \> 100 cc
* Patients are willing and able to give consent
Exclusion Criteria
* Patients who are unable to provide consent
* Patients who are suspected or known to be pregnant
18 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
M.D. Anderson Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gregory Reece, MD
Role: PRINCIPAL_INVESTIGATOR
M.D. Anderson Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
M D Anderson Cancer Center
Houston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
University of Texas MD Anderson Cancer Center Website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2018-00944
Identifier Type: REGISTRY
Identifier Source: secondary_id
2016-0463
Identifier Type: OTHER
Identifier Source: secondary_id
2016-0463
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.